AB KN Energies (hereinafter – KN, the Company) announces the unaudited consolidated (hereinafter – the Group) and separate financial results for the 3 months ended 31 March 2025. Key financial indicators for the 1- 3 months of 2025: EUR millionsGroupCompany 1-3 months of 20251-3 months of 20241-3 months of 20251-3 months of 2024Revenue25.324.4<td style="width:121.8px;;vertical-align: middle; text-align: left; pa ...

Core Viewpoint - Trifork Group has initiated a share buyback program, allowing the company to repurchase shares up to a total of DKK 14.92 million (approximately EUR 2 million) from 4 March 2025 to 30 June 2025 [1][2]. Group 1: Share Buyback Program Details - The share buyback program is in accordance with Regulation No. 596/2014 and Commission Delegated Regulation (EU) 2016/1052 [1]. - As of the latest report, Trifork has repurchased a total of 94,974 shares for a total amount of DKK 8,268,765, with an average purchase price of DKK 87.06 [2]. - Prior to the buyback, Trifork held 256,329 treasury shares, which represented 1.3% of the share capital [2]. Group 2: Utilization of Repurchased Shares - On specific dates (25 March, 25 April, and 23 May 2025), 4,370 shares from the buyback were used for the Executive Management's monthly fixed salary, transitioning from cash payment to partial share payment [3]. - Additionally, on 1 April 2025, 19,943 shares were utilized for the RSU plan for Executive Management and certain employees [3]. Group 3: Current Treasury Shares and Outstanding Shares - Following the transactions, Trifork now holds a total of 326,016 treasury shares, which corresponds to 1.7% of the total registered shares [4]. - The total number of registered shares in Trifork is 19,744,899, leading to 19,417,909 outstanding shares after adjusting for treasury shares [4].

Company Overview - BW Offshore is engaged in engineering innovative floating production solutions and operates a fleet of Floating Production Storage and Offloading (FPSO) units with ambitions for growth [3] - The company has approximately 1,100 employees and is publicly listed on the Oslo stock exchange [3] Upcoming Financial Results - BW Offshore will release its Q1 2025 results on June 2 at 07:30 CEST [1] - A conference call will be hosted by CEO Marco Beenen and CFO Ståle Andreassen on the same day at 09:00 CEST, which will include a Q&A session [1] Conference Call Details - The presentation can be followed via a webcast with supporting slides and a Q&A module, available on the company's website [2] - There will be a 30-second delay for those following the webcast compared to the main conference call, and it is recommended to use an updated browser, preferably Chrome [2]

Wereldhave and Sofidy (Tikehau Group), a leading European real estate investment and asset management firm, have partnered on the acquisition of shopping center Stadshart Zoetermeer, and parking garages, in Zoetermeer, the Netherlands, from Unibail-Rodamco-Westfield. The asset has a total gross lettable area of approximately 59,000 m² (excluding parking). This acquisition marks Wereldhave’s first joint venture and aligns fully with the company’s strategy and acquisition criteria. Wereldhave will act as asse ...

Core Viewpoint - Biotalys has appointed Luc Van fraeyenhoven as the new Chief Financial Officer (CFO) to lead finance operations as the company advances its product pipeline towards commercialization [2][4]. Company Overview - Biotalys is an Agricultural Technology (AgTech) company focused on developing protein-based biocontrol solutions aimed at providing alternatives to conventional chemical pesticides for sustainable crop protection [5]. - The company utilizes its AGROBODY™ technology platform to create a diverse pipeline of product candidates targeting key crop pests and diseases [5]. - Founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology), Biotalys has been listed on Euronext Brussels since July 2021 and is based in Ghent, Belgium [5]. Leadership Transition - Luc Van fraeyenhoven, with over three decades of financial experience, will succeed Douglas Minder as CFO [2][3]. - Van fraeyenhoven has held CFO positions in various biotechnology and medtech companies, including Arseus Medical and ActoBio Therapeutics, and has significant experience in finance operations and strategy [3]. - The transition is expected to occur over the next few months, with Van fraeyenhoven expressing eagerness to contribute to Biotalys' innovative technology [2][4]. Strategic Importance - The appointment of Van fraeyenhoven is seen as crucial for Biotalys as it seeks to commercialize its first products while managing resources effectively [4]. - The leadership change is anticipated to enhance financial guidance on both long-term strategies and daily operations [4].

Core Viewpoint - Questerre Energy Corporation is responding to a recent ruling by the Court of Appeal of Quebec regarding Bill 21, which affects petroleum exploration and production in the region, and plans to appeal to the Supreme Court of Canada [2][3]. Legal Context - The Court of Appeal recognized serious constitutional issues with Bill 21 and reinstated certain provisions, allowing the Quebec government to potentially enforce abandonment and reclamation of existing wells [2]. - The ruling overturned a previous decision by the Quebec Superior Court that had suspended key provisions of Bill 21 [2][3]. - The Court of Appeal found that the original Justice erred in the balance of convenience test and did not adequately consider the public interest in suspending Bill 21 [3]. Company Overview - Questerre is positioned as an energy technology and innovation company, focusing on responsibly producing and utilizing energy through clean technologies [4]. - The company emphasizes the importance of balancing economics, environment, and society for the future success of the oil and gas industry [5].

Company Overview - Sernova Biotherapeutics is a clinical-stage company focused on developing regenerative medicine therapeutics, specifically its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D) [3] - The company collaborates with Evotec to create Bio-hybrid Organs that integrate human donor cells or stem-cell derived islet-like clusters with its Cell Pouch [3] Recent Developments - Mr. Ross Haghighat resigned as Chair of Sernova Biotherapeutics on May 24, 2025, and his resignation was accepted by the Board of Directors [2] - The Board expressed gratitude for Mr. Haghighat's service and wished him well in his future endeavors [2] Product Focus - The Bio-hybrid Organ developed by Sernova consists of non-biomaterials, such as the Cell Pouch, combined with living tissues to restore or enhance the function of compromised organs [3] - The initial focus of Sernova's innovative approach is on treating chronic diseases, particularly T1D and thyroid disorders [3]

Core Viewpoint - Canyon Resources Limited has secured a medium-term syndicated credit facility of approximately US$140 million from AFG Bank Cameroon to fund the development of its Minim Martap Bauxite Project in Cameroon, alongside additional funding from its major shareholder, Eagle Eye Asset Holdings [1][2][7]. Group 1: Credit Facility Details - The credit facility amounts to XAF 82,000,000,000 (approximately US$140 million) and is structured as a syndicated medium-term loan [11]. - The interest rate for the facility is fixed at 8.00% per annum plus VAT, with a repayment term of 8 years from the first drawdown [11]. - The drawdown is anticipated to occur in Q3 2025, with conditions including the opening of project accounts and guarantees from Canyon Resources Limited [3][11]. Group 2: Project Development - The funds from the credit facility will be utilized for acquiring locomotives, wagons, and developing rail and port infrastructure for the Minim Martap Bauxite Project [2]. - Since obtaining the Mining License in September 2024, Canyon has made significant progress, including securing key land for port and rail facilities, and is now focused on making a Final Investment Decision [5][6]. - The company aims to commence its first shipment of bauxite from Minim Martap in the first half of 2026 [5]. Group 3: Stakeholder Support - Eagle Eye Asset Holdings intends to exercise 350 million options for AU$24.5 million to further support the funding of Stage One operations at Minim Martap [2][7]. - AFG Bank Cameroon is recognized as a strong partner for Canyon, demonstrating expertise in structured financing and commitment to providing tailored financial solutions [4][7].

Core Viewpoint - Glass Lewis, an independent proxy advisory firm, has recommended that stockholders vote "FOR" the compensation proposal for Radware's president and CEO at the upcoming Extraordinary General Meeting [1][2] Group 1: Compensation Proposal - The annual bonus and long-term equity incentives for Radware's president and CEO are found to be appropriately aligned with performance and market practices [2] - The compensation structure has been modified to enhance the alignment of pay and performance, benefiting shareholders [3] Group 2: Meeting Details - The Extraordinary General Meeting will take place on May 29, 2025, at 8:00 a.m. (EDT) at Radware's offices in Mahwah, N.J. [3] - The record date for the Meeting is April 25, 2025 [3] Group 3: Company Overview - Radware is a global leader in application security and delivery solutions for multi-cloud environments, utilizing AI-driven algorithms for real-time protection against sophisticated cyber threats [6]

– Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world setting – – Lorundrostat 50 mg dosed once daily demonstrated clinically meaningful and sustained reductions in systolic blood pressure, with a 16.9 mmHg reduction at Week 6 (-9.1 mmHg placebo adjusted) and a 19.0 mmHg reduction at Week 12 (-11.7mm placebo adjusted) – – Lorundrostat demonstrated a favorable s ...